Aileron Therapeutics (NASDAQ:ALRN) Stock Price Up 6.2%

Aileron Therapeutics Inc (NASDAQ:ALRN)’s stock price rose 6.2% during mid-day trading on Tuesday . The company traded as high as $0.52 and last traded at $0.51, approximately 122,939 shares changed hands during mid-day trading. A decline of 63% from the average daily volume of 331,022 shares. The stock had previously closed at $0.48.

ALRN has been the topic of a number of research reports. Zacks Investment Research downgraded Aileron Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Aileron Therapeutics in a research note on Monday, September 30th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $4.00.

The company has a current ratio of 4.12, a quick ratio of 4.12 and a debt-to-equity ratio of 0.21. The stock has a 50 day simple moving average of $0.49 and a 200-day simple moving average of $0.65. The firm has a market cap of $13.90 million, a P/E ratio of -0.24 and a beta of 2.28.

Aileron Therapeutics (NASDAQ:ALRN) last announced its earnings results on Thursday, November 7th. The company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). As a group, equities analysts forecast that Aileron Therapeutics Inc will post -1.26 earnings per share for the current fiscal year.

In other news, Director Rickenbach Josef H. Von bought 113,145 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was acquired at an average cost of $0.98 per share, with a total value of $110,882.10. In the last 90 days, insiders have purchased 148,897 shares of company stock valued at $129,514. 6.20% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Aileron Therapeutics by 261.6% during the 2nd quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock valued at $240,000 after buying an additional 240,910 shares in the last quarter. Virtu Financial LLC grew its stake in Aileron Therapeutics by 195.0% during the 3rd quarter. Virtu Financial LLC now owns 66,946 shares of the company’s stock valued at $45,000 after purchasing an additional 44,253 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Aileron Therapeutics by 179.6% during the 2nd quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock valued at $36,000 after purchasing an additional 31,787 shares during the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

About Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Recommended Story: How to Invest in Stocks with Increasing Dividends

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.